Mutations that inactivate CaSR (i.e., result in loss-of-function) cause familial hypocalciuric hypercalcemia (FHH) and neonatal severe primary hyperparathyroidism (NSHPT) [8], [9]. The gene discussed is CASR; the disease is familial hypocalciuric hypercalcemia.